Robert Francis Oatfield, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2641 Seminary Hill Rd, Centralia, WA 98531 Phone: 313-384-9948 |
Dr. Rachel Norianne Arnold, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1720 Cooks Hill Rd, Centralia, WA 98531 Phone: 360-827-8100 Fax: 360-827-8120 |
Daniel Kingsley Lowe, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1720 Cooks Hill Rd, Centralia, WA 98531 Phone: 360-736-1195 Fax: 360-736-4952 |
Sally Maria Ehlers, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1720 Cooks Hill Rd, Centralia, WA 98531 Phone: 360-736-1195 Fax: 360-736-4952 |
Mark Gilbert Ropka, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1720 Cooks Hill Rd, Centralia, WA 98531 Phone: 360-736-1195 Fax: 360-736-4952 |
Emery J Chang, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1720 Cooks Hill Rd, Pmg Sw Wa Centralia Gen Surg, Centralia, WA 98531 Phone: 360-736-1195 |
Brittany Leigh Tabler, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1720 Cooks Hill Rd, Centralia, WA 98531 Phone: 360-827-8100 Fax: 360-827-8120 |
Atul Thakker, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1720 Cooks Hill Rd, Centralia, WA 98531 Phone: 360-736-1195 Fax: 360-736-4952 |
Dr. Huan Yan, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1720 Cooks Hill Rd, Centralia, WA 98531 Phone: 360-827-8100 Fax: 360-827-8120 |
News Archive
Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee ("ODAC") will review CTI's New Drug Application ("NDA") for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") on March 22, 2010.
A recently completed study indicates that Finnish children who spend a lot of time in front of screens have a heightened risk for overweight and abdominal obesity, regardless of the extent of their physical activity.
The theory that depression is caused by a chemical imbalance is often presented in the media as fact even though there is little scientific evidence to support it, according to a new study co-authored by a Florida State University visiting lecturer.
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the close of its $16 million Series D round of financing. Current investors Caxton Advantage Life Sciences Fund LP and Sanderling Venture Partners co-led the round. In addition, the Series D structure grants certain current investors the option to invest an additional $4 million in this financing round in the future.
Ockham Development will partner with the Leukemia and Lymphoma Society of North Carolina chapter during 2014 to increase its commitment to cancer-directed philanthropy and collaborate with the Society to support the company's personal health and fitness goals.
› Verified 2 days ago